Comprehensive molecular profiling of 5,175 esophagogastric cancer (EGC) patients identified distinct molecular signatures for early-onset (< 50 years of age, EOEGC, n=530) versus average-onset (AOEGC, n=4,645) tumors.
EOEGC has increased frequency of CDH1 mutations, ARHGAP26 fusions, enrichment of epithelial mesenchymal transition (EMT) and angiogenesis pathways, decreased MAPK pathway activity, decreased frequency of TMB-high and dMMR/MSI-H, and a unique immune cell infiltrate with decreased M1 macrophages and increased M2 macrophages.
These unique differential characteristics present therapeutic opportunities but also demonstrate the limitations of currently approved therapies in this subset of patients.
Abstract Improved clinical outcomes are reported for patients with advanced pancreatic adenocarcinoma (PDAC) treated with first-line FOLFIRINOX/NALIRIFOX, but elderly patients with comorbidities are more often… […]
Adult Sarcomas with NTRK Fusions: Clinicopathologic and Genomic Heterogeneity
Simple Summary Adult sarcomas harboring NTRK fusions are rare and represent a biologically heterogeneous group with diverse morphologic, genomic, and clinical features. In this retrospective… […]
